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Background: Chronic Fatigue Syndrome (CFS) is a neuroimmunoendocrine disease affecting about 1% of the US
population, mostly women. It is characterized by debilitating fatigue for six or more months in the absence of
cancer or other systemic diseases. Many CFS patients also have fibromyalgia and skin hypersensitivity that worsen
with stress. Corticotropin-releasing hormone (CRH) and neurotensin (NT), secreted under stress, activate mast cells
(MC) necessary for allergic reactions to release inflammatory mediators that could contribute to CFS symptoms.
Objective: To investigate the effect of isoflavones on the action of polyinosinic:polycytidylic acid (poly(I:C)), with or without
swim stress, on mouse locomotor activity and inflammatory mediator expression, as well as on human MC activation.
Methods: Female C57BL/6 mice were randomly divided into four groups: (a) control/no-swim, (b) control/swim, (c)
polyinosinic:polycytidylic acid (poly(I:C))/no swim, and (d) polyinosinic:polycytidylic acid (poly(I:C))/swim. Mice were
provided with chow low or high in isoflavones for 2 weeks prior to ip injection with 20 mg/kg poly(I:C) followed or not
by swim stress for 15 minutes. Locomotor activity was monitored overnight and animals were sacrificed the following
day. Brain and skin gene expression, as well as serum levels, of inflammatory mediators were measured. Data were
analyzed using the non-parametric Mann-Whitney U-test.
Results: Poly(I:C)-treated mice had decreased locomotor activity over 24 hours, and increased serum levels of TNF-α, IL-6,
KC (IL-8/CXCL8 murine homolog), CCL2,3,4,5, CXCL10, as well as brain and skin gene expression of TNF, IL-6, KC (Cxcl1, IL8
murine homolog), CCL2, CCL4, CCL5 and CXCL10. Histidine decarboxylase (HDC) and NT expression were also increased,
but only in the skin, over the same period. High isoflavone diet reversed these effects.
Conclusion: Poly(I:C) treatment decreased mouse locomotor activity and increased serum levels and brain and skin gene
expression of inflammatory mediators. These effects were inhibited by isoflavones that may prove useful in CFS.
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Chronic Fatigue Syndrome (CFS) is a complex disease,
which has also been called ‘neurasthenia’, ‘post viral fatigue’,
and ‘chronic mononucleosis’ [1-3]. Its prevalence may be
as high as 1% in the US population [4] with a female to
male ratio of 4 to 1 [5]. CFS involves the muscular, ner-
vous, hormonal and immune systems. Patients complain* Correspondence: theoharis.theoharides@tufts.edu
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unless otherwise stated.of overwhelming fatigue, sleep disturbances, malaise,
muscle aches, gastrointestinal symptoms, dizziness on
standing, and cognitive problems [6]. Clinical and subclin-
ical viral infections have been suspected, but never con-
firmed [7,8].
CFS is often comorbid with other disorders, includ-
ing fibromyalgia, Pelvic Bladder Syndrome/Interstitial
Cystitis (PBS/IC), irritable bowel syndrome (IBS), and
migraines [9], all of which are characterized by central
nervous system (CNS) dysfunction [10], and worsened
by stress [11-15]. Many CFS patients demonstrate ab-
normal hypothalamic-pituitary-adrenal (HPA) axis ac-
tivity [16,17]. Anxiety is common in CFS [18] andLtd. This is an Open Access article distributed under the terms of the Creative
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CFS symptoms could derive from the possible release of
inflammatory mediators that could affect brain function
[19,20]. As of today, there are no FDA approved drugs
for the treatment of CFS [21]; psychological, physical,
and pharmacological interventions used currently are
not very effective [22].
An abnormal immune component may be involved in
CFS [23-25], but the neuroimmune and neuroendocrine
interactions involved are still unknown [26]. Mast cells
(MC) and their mediators have been implicated in all
diseases that are comorbid with CFS [9]. There is higher
number of skin MC in patients with CFS [27,28], and
such patients also show increased skin hypersensitivity
[29]. Furthermore, CFS also occurs more often in pa-
tients with chronic urticaria, that also involves MC [30].
In fact, there is hyperresponsiveness in the bronchi of
CFS patients, implying MC activation [31].
Activated MC release a number of chemokines and
cytokines that could contribute to CFS symptoms
[32,33]. MC are located perivascularly in close proxim-
ity to neurons [34], especially in the diencephalon
[35,36], where functional MC-neuron interactions have
been documented [36,37] in response to corticotropin-
releasing hormone (CRH) [38]. In vivo activation of MC
by CRH is augmented by neurotensin (NT) [39]. More-
over, NT is induced in the hypothalamus in response to
bacterial lipopolysaccharide (LPS) and regulates the
HPA axis [40].
Unfortunately, there are neither effective CFS treat-
ments nor human MC inhibitors clinically available that
may also be used in CFS. Flavonoids are natural com-
pounds with strong antioxidant and anti-inflammatory
activity [41]. Certain flavonoids also inhibit MC [42]
and have neuroprotective effects [41,43].
Here we report that treatment of mice with poly(I:C)
results in reduced locomotor activity and increased
serum levels, as well as brain and gene expression, of in-
flammatory mediators, all of which are reversed by
treatment with the isoflavones daidzein and genistein.Methods
Chemicals and reagents
Polyinosinic-polycytidylic acid-TLR3-based adjuvant, poly
(I:C), HMW VacciGrade, (catalog# vac-pic) was purchased
from Invivogen (San Diego, CA, USA). Substance P (SP,
catalog# S6883), neurotensin (NT, catalog# N6383) and
corticotropin-releasing hormone (CRF, catalog# C3042)
were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Aliquots of the above were prepared according to
the manufacturer’s instructions. Teklad lab animal diets
(catalog# 2918X, and 2920X) were purchased from Harlan
(Indianapolis, IN, USA).Animals
C57BL/6 female mice, nine to twelve weeks old, (Jackson
Laboratories, Bar Harbor, ME, USA) were kept in virus-free
sections of a modern animal facility and were allowed ad
libitum access to food and water. They were maintained on
a 14:10 hour light-dark cycle (the standard light-dark cycle
used by the Department of Animal Health). Female mice
were chosen because published reports indicate a female to
male ratio of 4:1 [5], while the US Centers for Disease Con-
trol and Prevention (CDC) specify a female to male ratio of
4:1 [5]. Mice were kept in cages of five mice/cage until the
day of the experiments. Both low and high isoflavone diets
(2018X and 2020X) were sterile with similar ingredients
other than isoflavone content. We monitored weight
changes for 21 days prior to the beginning of the experi-
ments. Only poly(I:C)/no swim-treated mice showed a
slight decrease in weight change. Poly(I:C)/swim-treated
mice, as well as their corresponding control mice, slightly
increased their weight over the three-week observation
period. However, by the end of this period, there was no
statistical difference in weight change. The protocol was ap-
proved by Tufts Medical Center IACUC under number B
2011-88.
Treatment conditions
Mice were provided with chow containing either non-
detectable to low (ND-20 mg/kg, Teklad 2920X) or high
(150 to 250 mg/kg, Teklad 2918X) isoflavone (daidzein
plus genistein) levels for two weeks. Conditions included
four groups: (a) control (normal saline intraperitoneal
(ip) injection)/no swim, (b) control/swim, (c) poly(I:C)/
no swim, and (d) poly(I:C)/swim (n = 5 to 7/group). Mice
were injected ip with 20 mg/kg of poly(I:C) or normal sa-
line the first day. Subsequently, they were subjected to
swim for 15 minutes, individually in a transparent plastic
cylindrical jar (17 cm× 25 cm) containing 15 cm-deep
water at room temperature (23 ± 1°C). This approach re-
flects both exercise and the stress of water immersion.
Mice were then placed individually into specific cages and
locomotor activity was monitored overnight.
Assessment of behavioral parameter-locomotor activity
After the experimental procedures, animals were placed
individually into standard plastic housing cages with food
and water available ad libitum and overnight locomotor
activity (for a total of 16 hours) was monitored with the
Neuroscience Behavior Core’s mouse SmartFrame® Cage
Rack System (Kinder Scientific, Poway, CA, USA). This
system consists of 20 PC-interfaced horizontal photobeam
frames. The frame (containing 12 photocells; arranged on
a 8 L × 4 W grid) surrounds one home cage environment
and continuously tracks the animal’s movement. This fully
automated system allows the user to quantify horizontal
ambulation by counting breaks in infrared photocell
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Scientific, Poway, CA, USA). Data were collected and sub-
sequently analyzed in time bins (every hour) or as a total
over the course of collection to the ‘Total Distance
Travelled’ (in cm) parameter for each zone.
Sample collection
Mice were euthanized 24 hours post poly(I:C) ip injec-
tion using isoflurane overdose and thoracotomy. Blood
was collected by cardiac puncture and was used to de-
termine inflammatory mediator levels in the serum.
Brain (diencephalon) and skin (back shaved with a elec-
tric shaver the day before) samples were collected and
immersed into RNAlater (catalog# AM7021) purchased
from Invitrogen (Grand Island, NY, USA). Samples were
stored at -80°C.
Serum levels of inflammatory mediators
TNF-α, VEGFα, IL-1α, IL-1β, IL-4, IL-6, KC (IL-8/(CXC
motif ) ligand (CXC)L8 murine homolog, IL-9, IL-10,
IL-12p70, IL-17, (CC motif ) ligand (CCL)2, CCL3,
CCL4, CCL5, CXCL10 and IFNγ mouse serum levels
were determined using the MILLIPLEX MAP Mouse
Cytokine/Chemokine Magnetic Bead Assay (MCYTO-
MAG-70 K custom made panel for the specific analytes
mentioned above). Measurements were performed blindly
by Millipore (St. Charles, MI, USA). Millipore's minimum
assay reporting range for TNF-α and IL-6 levels was
32 pg/ml, for CCL2 was 800 pg/ml, while for CCL3 and
CCL4 it was 160 pg/ml. Therefore, we consider all
values < × pg/ml as equal to x pg/ml.
Quantitative PCR
Total RNA from mouse tissues was extracted using
RNeasy Plus Mini kit (catalog# 74134) and RNeasy Fi-
brous Tissue Mini Kit (catalog# 74704), purchased from
QIAGEN (Valencia, CA, USA). Reverse transcription was
performed with 300 ng of total RNA using the iScript
cDNA synthesis kit (catalog# 170-8891) purchased from
Bio-Rad (Hercules, CA, USA). Real-time quantitative
polymerase chain reaction (qPCR) was carried out in a
7300 Sequence Detector, according to TaqMan Gene Ex-
pression Assay instructions from Life Technologies, Ap-
plied Biosystems (Grand Island, NY, USA) using Taqman
primer/probe sets (Additional file 1: Table S1). Samples
were analyzed for Tnf (TNF-α), Il4, Il6 (IL-6), KC (Cxcl1,
IL-8 homolog in the mouse), Ccl2 (CCL2), Ccl4 (CCL4),
Ccl5 (CCL5), Cxcl10 (CXCL10), histidine decarboxylase-
Hdc (HDC), and Nts (NT) gene expression using Gapdh
as internal control.Thermal cycling proceeded at 50°C for
2 minutes, 95°C for 10 minutes, 95°C for 15 seconds, for
40 cycles, and 60°C for 1 minute. Negative controls in-
cluded samples with water instead of template. Assays
were performed in triplicate for each data point. Resultswere normalized against the endogenous gene GAPDH
and were expressed relative to the mean of the control for
each gene (relative fold change).
Statistical analysis
Data were analyzed using the non-parametric Mann-
Whitney U-test. Results are presented as mean ± SE.
Statistical significance is defined as P < 0.05. We ana-
lyzed separately the different treatment subgroups
within each dietary group, using Mann-Whitney U-test
to compare poly(I:C)/no swim and poly(I:C)/swim-
treated mice with the control/no swim and control/
swim-treated groups, accordingly. We then analyzed the
same treatment subgroups between the two dietary
groups, using Mann-Whitney U-test to compare, for ex-
ample, poly(I:C)/swim-treated mice with low isoflavone
diet to poly(I:C)/swim-treated mice that were provided
with high isoflavone diet. Due to space limitations, we
submitted figures composed of all the experimental con-
ditions from the two different diets and all the statistical
significant results were marked in these figures.
Results
Effect of poly(I:C) and isoflavones on locomotor activity
Poly(I:C)/swim and poly(I:C)/no swim-treated mice on
low isoflavones had reduced maximum (max) locomotor
activity (over the 10-hour night period), denoted by the
dark bar (P = 0.008 and P = 0.036) compared to the con-
trol/swim and control/no swim-treated mice, respect-
ively (Figure 1A). High isoflavone chow reversed this
decrease (Figure 1B), and the difference between the two
diets was statistically significant (P = 0.032).
Effect of poly(I:C) and isoflavones on serum inflammatory
mediators
Poly(I:C)-treated mice on low isoflavones had increased
serum levels of TNF-α (Figure 2A), IL-6 (Figure 2B), KC
(Figure 2C), and CCL4 (Figure 2D), as well as CCL2,
CCL3, CCL5, and CXCL10 (Additional file 2: Table S2).
High isoflavones reduced the poly(I:C)-increased serum
levels of all the inflammatory markers. All IFNγ, IL-1β,
IL-4, IL-9, IL-10, IL-12p70, IL-17 and VEGFα serum
levels were below the detection limit, while IL-1α serum
levels were similar between the different treatment
groups. Swim stress augmented the poly(I:C) effect on
TNF-α, CCL4, and CCL5 serum levels.
More specifically, TNF-α serum levels in poly(I:C)/
swim-treated mice on low isoflavones were increased
(55 ± 14 pg/ml) compared to control/swim-treated mice
(32 ± 0 pg/ml, P = 0.0011) and poly(I:C)/no swim-
treated mice (37 ± 10 pg/ml,P = 0.0221). High isofla-
vones decreased these high TNF-α serum levels (32 ±
0 pg/ml, P = 0.0042) (Figure 2A). IL-6 serum levels in
poly(I:C)-swim and poly(I:C)/no swim-treated mice on
Figure 1 Polyinosinic:polycytidylic acid (poly(I:C)) and isoflavone effect on mouse locomotor activity. Mice were provided with either low
(Figure 1A) or high (Figure 1B) isoflavone diet ad libitum. Mice were injected intraperitoneally (ip) with 20 mg/kg poly(I:C) and were forced to
swim for 15 minutes. Following this, they were individually placed into specific cages and locomotor activity was monitored overnight.
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and 141 ± 11 pg/ml) compared to the corresponding
control/swim and control/no swim mice on low isoflavones
(32 ± 0 pg/ml, P = 0.0011 and 32 ± 0 pg/ml, P = 0.0114)
(Figure 2B). High isoflavones reduced IL-6 serum levels of
poly(I:C)/swim-treated mice (35 ± 5 pg/ml, P = 0.0054)
and poly(I:C)/no swim-treated (32 ± 0 pg/ml, P = 0.0298)
compared to the corresponding groups on low isoflavones
(Figure 2B).
Similarly, KC serum levels in poly(I:C)-treated mice
on low isoflavones were increased (735 ± 579 pg/ml
and 626 ± 523 pg/ml) compared to the corresponding
controls (173 ± 43 pg/ml, P = 0.0379 and 132 ± 52 pg/ml,
P = 0.0006, respectively) (Figure 2C). Although KC serum
levels in poly(I:C)/swim-treated mice on high isoflavones
were also increased (451 ± 107 pg/ml) compared to
control poly(I:C)/swim-treated mice (100 ± 45 pg/ml,
P = 0.0079), high isoflavone diet decreased KC serum
levels in poly(I:C)/no swim-treated mice (128 ± 43 pg/ml,
P = 0.0025) compared to those on low isoflavones
(Figure 2C).
Moreover, CCL4 serum levels were increased in poly
(I:C)-treated mice on low isoflavones (1,256 ± 556 pg/ml
and 395 ± 245 pg/ml) compared to the corresponding
controls (160 ± 0 pg/ml, P = 0.0011 and 160 ± 0 pg/ml,
P = 0.0037, respectively) (Figure 2D). Swim further
increased CCL4 serum levels (1,256 ± 556 pg/ml,
P = 0.0023). Although CCL4 serum levels in poly(I:C)-
treated mice on high isoflavones were also increased
(217 ± 55 pg/ml and 265 ± 111 pg/ml) compared to their
controls (160 ± 0 pg/ml, P = 0.0075 and 160 ± 0 pg/ml,
P = 0.0254, respectively)., high isoflavones decreasedCCL4 serum levels in poly(I:C)/swim-treated mice (217 ±
55 pg/ml, P = 0.0025) (Figure 2D).
Poly(I:C) treatment also increased CCL2, CCL3, CCL5
and CXCL10 serum levels and high isoflavones reduced
those increases (Additional file 3).Effect of poly(I:C) and isoflavones on brain gene
expression of inflammatory mediators
TNF-α (Figure 3A), IL-6 (Figure 3B), KC (Figure 3C),
CCL4 (Figure 3D), as well as CCL2, CCL5 and CXCL10
brain gene expression were increased in the poly(I:C)-
treated mice. High isoflavones reduced the increased
TNF, IL6, KC, CCL4 and CCL2 brain gene expression.
There was no difference in HDC and NT gene expres-
sion between the different treatment groups (Additional
file 4: Table S3).
More specifically TNF-α gene expression was increased
in the brain of poly(I:C)-treated mice on low isoflavones
(relative fold change of 22 ± 7 and 12 ± 9) compared to
their controls (1.1 ± 0.9, P = 0.0006 and 1 ± 0.7, P = 0.0012,
respectively) (Figure 3A). Although poly(I:C)-treated
mice on high isoflavones had increased TNF-α brain
gene expression (6 ± 1 and 9 ± 8) compared to their cor-
responding controls (1.2 ± 0.5, P = 0.0079 and 1 ± 0.3,
P = 0.0079, respectively), high isoflavones decreased
TNF-α gene expression in the brain of poly(I:C)/swim-
treated mice (6 ± 1, P = 0.0025) compared to those on low
isoflavones (Figure 3A). There was no effect of poly(I:C)
treatment on IL-6 brain gene expression (Figure 3B),
but high isoflavones still decreased IL-6 gene expression
in the brain of poly(I:C)/swim-treated mice (0.5 ± 0.1,
Figure 2 Polyinosinic:polycytidylic acid (poly(I:C)) and isoflavone effect on serum levels of inflammatory mediators. Mice were provided with
either low or high isoflavone diet ad libitum. Mice were injected intraperitoneally (ip) with 20 mg/kg poly(I:C) and were forced to swim for 15 minutes.
Following this, they were individually placed into specific cages and locomotor activity was monitored overnight. The next day, serum samples were
collected and analyzed for TNF-α (Figure 2A), IL-6 (Figure 2B), KC (Figure 2C), and CCL4 (Figure 2D) using the Milliplex microbead assay.
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2.4) (Figure 3B).
KC gene expression in the brain of poly(I:C)-treated mice
on low isoflavones was increased (18 ± 13 and 40 ± 52)
compared to their controls (0.9 ± 0.3, P= 0.0006 and 1 ± 0.3,
P= 0.0183, respectively) (Figure 3C). Although poly(I:C)/
swim-treated mice on high isoflavones still had increased KC
gene expression in their brain (2 ± 0.9) compared to control/
swim-treated mice (0.6 ± 0.1, P = 0.0159), high isofla-
vones reduced this increase in KC gene expression (2 ± 0.9,
P = 0.0177) compared to poly(I:C)/swim-treated mice
on low isoflavones (Figure 3C).
Likewise, CCL4 gene expression in the brain of poly(I:C)-
treated mice on low isoflavones was also increased (6.5 ± 4
and 2.9 ± 1.6) compared to their controls (1 ± 0.3, P= 0.0006
and 1 ± 0.4, P = 0.0350, respectively) (Figure 3D). Although,poly(I:C)/swim-treated mice on high isoflavones still had in-
creased CCL4 gene expression (1.8 ± 0.4) compared to con-
trol/swim-treated mice (1 ± 0.4, P= 0.0317), high isoflavones
reduced this increase in CCL4 gene expression (1.8 ± 0.4,
P= 0.0101) compared to poly(I:C)/swim-treated mice on
low isoflavones (Figure 3D). Poly(I:C) treatment also in-
creased CCL2, CCL5 and CXCL10 gene expression in the
brains of the mice. High isoflavones reduced this noted
CCL2 brain gene expression increase (Additional file 3).
Effect of poly(I:C) and isoflavones on skin gene
expression of inflammatory mediators
TNF-α (Figure 4A), IL-6 (Figure 4B), KC (Figure 4C),
CCL4 (Figure 4D), as well as CCL2, CCL5 and CXCL10
(Additional file 5: Table S4) skin gene expression were
increased in the poly(I:C)-treated mice. Moreover, HDC
Figure 3 Polyinosinic:polycytidylic acid (poly(I:C)) and isoflavone effect on brain gene expression of inflammatory mediators. Mice were
provided with either low or high isoflavone diet ad libitum. Mice were injected intraperitoneally (ip) with 20 mg/kg poly(I:C) and were forced to
swim for 15 minutes. Following this, they were individually placed into specific cages and locomotor activity was monitored overnight. The next
day, brain samples were collected and analyzed for TNF-α (Figure 3A), IL-6 (Figure 3B), KC (Figure 3C), and CCL4 (Figure 3D) brain gene expression
using qPCR.
Vasiadi et al. Journal of Neuroinflammation 2014, 11:168 Page 6 of 12
http://www.jneuroinflammation.com/content/11/1/168and NT gene expression were also increased in the skin
(Figure 5A and B). High isoflavone diet reduced the in-
creased TNF-α, IL-6 and KC skin gene expression.
More specifically, TNF-α gene expression in the skin
of poly(I:C)/swim-treated mice on low isoflavones, was
increased (5 ± 0.9) compared to their controls (1.1 ± 0.4,
P = 0.0006) (Figure 4A) and high isoflavones decreased
this increase in TNF-α gene expression (2.3 ± 1.3,
P = 0.0101) (Figure 4A). Likewise, IL-6 gene expression
in the skin of poly(I:C)-treated mice on low isoflavones
was increased (14 ± 4 and 22 ± 16) compared to their
controls (0.9 ± 0.8, P = 0.0006 and 1 ± 0.4, P = 0.0012,
respectively) (Figure 4B). Although poly(I:C)-treated
mice on high isoflavones still had increased IL-6 gene
expression (5.5 ± 3 and 3.4 ± 1.7) compared to their
controls (1.4 ± 0.7, P = 0.0079 and 0.7 ± 0.4, P = 0.0159,respectively), high isoflavones reduced this increase in the
IL-6 gene expression (5.5 ± 3 P = 0.0101) (Figure 4B).
Similarly, KC gene expression in the skin of poly(I:C)-
treated mice on low isoflavones was also increased (53 ±
55 and 69 ± 83) compared to their controls (0.3 ± 0.2,
P= 0.0021 and 1 ± 1.5, P= 0.0012, respectively) (Figure 4C).
High isoflavones reduced this increase in the KC gene ex-
pression of poly(I:C)-treated mice (2.8 ± 3.5, P = 0.0057
and 3.4 ± 1.9, P = 0.0043) (Figure 4C).
CCL4 gene expression was increased in the skin of poly
(I:C)-treated mice on low isoflavones (24 ± 15 and 21 ± 19)
compared to their controls (0.4 ± 0.3, P = 0.0021 and 1 ±
1.7, P = 0.0023, respectively) (Figure 4D). CCL4 gene ex-
pression was also increased in the skin of poly(I:C)-treated
mice on high isoflavones (20 ± 24 and 27 ± 20) compared to
their controls (0.8 ± 0.7, P = 0.0079 and 1 ± 1.3, P = 0.0079,
Figure 4 Polyinosinic:polycytidylic acid (poly(I:C)) and isoflavone effect on skin gene expression of inflammatory mediators. Mice were
provided with either low or high isoflavone diet ad libitum. Mice were injected intraperitoneally (ip) with 20 mg/kg poly(I:C) and were forced to
swim for 15 minutes. Following this, they were individually placed into specific cages and locomotor activity was monitored overnight. The next
day, skin samples were collected and analyzed for TNF-α (Figure 4A), IL-6 (Figure 4B), KC (Figure 4C) and CCL4 (Figure 4D) skin gene expression
using qPCR.
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reducing this increase.
In the same way, HDC gene expression was increased in
the skin of poly(I:C)-treated mice on low isoflavones (4 ± 2
and 4 ± 2) compared to their controls (0.6 ± 0.4, P = 0.0003
and 1 ± 0.8, P = 0.0123, respectively) (Figure 5A). HDC gene
expression was also increased in the skin of poly(I:C)-
treated mice on high isoflavones (3 ± 1.1 and 3 ± 1) com-
pared to their controls (0.9 ± 0.3, P = 0.0079 and 1 ± 0.2,
P = 0.0317, respectively).
Similar to HDC gene expression, NT gene expression
was increased in the skin of poly(I:C)-treated mice on low
isoflavones (8 ± 4 and 9 ± 10) compared to their controls
(0.6 ± 0.4, P = 0.0025 and 1 ± 0.7, P = 0.0012, respectively)
(Figure 5B). NT gene expression was also increased in the
skin of poly(I:C)-treated mice on high isoflavones (8 ± 4,and 6 ± 6) compared to their controls (1.9 ± 0.8, P = 0.0317
and 1 ± 0.2, P = 0.0079, respectively).
Finally, poly(I:C) treatment also increased CCL2, CCL5
and CXCL10 gene expression in the skin of the mice.
High isoflavones did not have any statistical effect on
CCL4, CCL2, CCL5, CXCL10, HDC and NT skin gene
expression (Additional file 5: Table S4).Discussion
Here we show that poly(I:C) significantly reduced loco-
motor activity over the first 24 hours, in comparison to
control mice. Forced swim did not have any effect on its
own, but augmented the effect of poly(I:C) on increas-
ing TNF-α, CCL3 and CCL5 serum levels. We also used
BALBc mice in an effort to investigate the possibility of
Figure 5 Polyinosinic:polycytidylic acid (poly(I:C)) and isoflavone effect on skin gene expression of inflammatory mediators. Mice were
provided with either low or high isoflavone diet ad libitum. Mice were injected intraperitoneally (ip) with 20 mg/kg poly(I:C) and were forced to
swim for 15 minutes. Following this, they were individually placed into specific cages and locomotor activity was monitored overnight. The next
day, skin samples were collected and analyzed for HDC (Figure 5A) and NT (Figure 5B) skin gene expression using qPCR.
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findings with C57BL/6 mice (results not shown).
Use of poly(I:C) increased serum levels of molecules
that have been associated with inflammation and fatigue
including TNF-α, IL-6, KC, CCL2, CCL3, CCL4, CCL5,
and CXCL10. Moreover, poly(I:C) also increased brain
and skin gene expression of TNF-α, IL-6, KC, CCL2,
CCL4, CCL5, CXCL10, while HDC and NT gene expres-
sion were only increased in the skin, suggesting that NT
and histamine may explain the skin findings in CFS pa-
tients. Forced swim stress had no additional effect to
that of poly(I:C), except for augmenting TNF-α serum
levels. TNF-α and IL-6 serum levels were actually in-
creased in CFS [20,44]. Such pro-inflammatory media-
tors can increase blood-brain barrier (BBB) permeability
[45] and permit entry of circulating leukocytes leading
to brain inflammation. TNF-α was shown to be released
along with histamine from rat brain MC [46], and was
involved in brain inflammation [47]. MC can also inter-
act with T cells [48-50] and superactivate them through
TNF-α [51].
Unlike our present results, one group reported that
daily forced swim stress for two to three weeks, with or
without an immunological trigger administered on day
one (lipopolysaccharide or Brucella abortus antigen), in-
duced ‘chronic fatigue’, but only in Albino laca mice
[52-55] and Wistar rats [56]. In these papers, behavioral
parameters, such as immobility time, time to start
grooming after swim stress, roda rod test, and elevated
plus maze test were increased indicating post stress fa-
tigue and anxiety. Also, biochemical measurements indi-
cative of brain oxidative stress were increased. In
another paper, BALBc mice were injected with Brucellaabortus and developed decreased running activity that
lasted one week [57]. Forced swim of Charles Foster al-
bino rats for twenty-one days also increased immobility
time, anxiety as assessed by elevated plus maze test, and
brain oxidative stress [58]. These findings maybe due to
the differences in the strains and triggers used.
Chemokines interact with their receptors and attract
immune cells to inflammation sites [59-61]. CXCR1,
CXCR2, CXCR3, CXCR4, CX3CR1, CCR1, CCR3, CCR4
and CCR5 are expressed by human MC of different ori-
gins [62]. Stimulated MC release CCL2, CCL3, CCL4
[63]. Murine fetal skin-derived cultured MC (FSMCs) re-
lease CCL3, CCL4, CCL5, IL-6 and TNF-α upon TLR3-
poly(I:C) activation [64,65]. Peritoneal MC from C57BL/
6 mice activated by poly(I:C)-TLR3 have increased CCL5
and CXCL10 expression [66,67].
Here we also show that poly(I:C) with or without NT
or CRH did not have any effect on TNF-α, CXCL8 and
VEGFα release from human cultured LAD2 MC (results
not shown), but increased only TNF-α gene expression
when used together with CRH, NT, or SP. Poly(I:C)
alone did not have any effect on human MC, but in-
creased TNF-α gene expression at 24 hours when used
together with CRH or NT.
Toll-like receptors’ (TLRs) [68,69] activation is import-
ant in the development of innate immunity to invading
pathogens, leading to release of different cytokines
[64,70,71]. Antigen-mediated MC reactivity is amplified
through prolonged TLR-ligand treatment [72].
Human umbilical cord blood-derived MC express
TLR-3, activation of which produced IFNα and IFNβ in
response to double-stranded RNA [73]. A recent publi-
cation reported that MC respond to intracellular, but
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TNF-α; moreover, infection of MC with live Sendai virus
induces an anti-viral response similar to that of intracel-
lular poly(I:C) [74].
We also used CRHR-1 knockout (KO) mice in order
to investigate the possible involvement of CRHR in any
stress effect. However, forced swim stress alone did not
have an effect and there was no difference using these
mice (results not shown). Nevertheless, rats exposed to
water immersion stress had a four-fold increase in
plasma histamine levels that was absent in W/Wv MC-
deficient rats [75]. Acute stress also increased serum
histamine and IL-6 levels, both of which were also ab-
sent in MC deficient W/Wv mice [76].
Here we also show that the isoflavones genistein and
daidzein reversed the effect of poly(I:C) on mice. Genistein
has been reported to attenuate muscle fatigue [77], protect
against endothelial barrier dysfunction [78] and suppress
LPS-induced inflammatory response in macrophages [79].
Isoflavones also suppress MC expression of the high affinity
IgE receptor (FcεRI) [80]. However, isoflavones have estro-
genic activity and may not be desirable in certain clinical
settings. The flavonoids epigallocatechin, naringin, and cur-
cumin ameliorated ‘chronic fatigue’ [53-56]. Other papers
reported similar effects for the Astragalus flavonoids [81]
and for the olive extract [82].
Flavonoids exert potent anti-inflammatory effects via
various pathways [83-87]. A review of human random-
ized controlled trial studies summarized some significant
benefits to cognitive function after isoflavone supple-
mentation [88]: improvements in executive function,
working memory and processing speed [88]. Specifically,
two studies reported significant effects of 60 mg/day
treatment with isoflavones in processing speed and psy-
chomotor speed [89,90].
Quercetin increases exercise tolerance in mice [91].
Oral administration of quercetin leads to accumulation
in brain tissue and attenuates the increased oxidative
stress in the hippocampus and striatum of rats exposed
to chronic forced swimming [92,93]. Quercetin has po-
tent anti-oxidant and anti-inflammatory activity [41,42],
and inhibits MC degranulation [94,95], as well as TNF-
α, IL-6, and IL-8 secretion [95,96]. Moreover, it reverses
acute stress-induced behavioral changes and reduces
brain glutathione levels in mice [97].
Recent studies with antigen-stimulated MC show that
epigallocatechin gallate (EGCG) inhibits MC degranulation,
leukotriene C4 secretion, as well as the production of TNF-
α, IL-6 and IL-8 [94,96]. The quercetin-related flavone
luteolin inhibits MC activation [98] and MC-dependent
stimulation of activated T cells [51]. Luteolin also inhibits
IL-6 release from microglia cells [99] and from astrocytes
[100]. Recent reviews have addressed the possible use of fla-
vonoids for the treatment of CNS diseases [101,102].Increasing evidence implicates CNS inflammation [103],
as well as MC-microglia interactions, in neuropsychiatric
diseases [104,105]. MC are important for allergic reac-
tions, but also in immunity [106,107], and inflammatory
diseases [15,108]. TLRs have also been implicated in CNS
dysfunction through MC and glial activation [104].
Conclusion
Here we report that treatment of mice with poly(I:C) re-
sulted in reduced locomotor activity and increased in-
flammatory markers in serum, brain and skin, all of
which were reversed by treatment with isoflavones. Our
findings also demonstrate significant variability among
mouse ‘models’ as was recently reported [109]. There is
need for the establishment of a more reliable animal
model for CFS. Nevertheless, certain flavonoids appear
promising for use in pilot clinical trials with CFS
patients.
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